http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H08509977-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 |
| filingDate | 1994-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1996-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H08509977-A |
| titleOfInvention | 8-Substituted xanthines as selective adenosine receptor agents |
| abstract | (57) [Summary] Xanthine derivatives having the structural formula (I), including the (R)-and (S) -enantiomers and racemic mixtures, and pharmaceutically acceptable salts thereof, wherein R 1 And R 2 are each independently (C 1 -C 4 ) lower alkyl or (C 2 -C 4 ) lower alkenyl, Z is (II) or (III) or (IV), R 3 is hydrogen, ( C 1 -C 3 ) lower alkyl, nitro, amino, hydroxy, fluoro, bromo, or chloro, R 4 is (C 1 -C 4 ) lower alkyl, and n is 1 or 2. From in-laboratory studies, it is known that specific physiological effects can be discerned as a result of this selectivity, and in-laboratory adenosine receptor activity correlates with in-vivo adenosine receptor activity. Formulations of the compounds of the invention enhance the physiological effects of minimizing other physiological effects, such as lowering blood pressure without reducing heart rate. It can be made based on binding activity. |
| priorityDate | 1993-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 218.